AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (8.4 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Neuron Foundry Mach 8: A Concept of Multi-modal Neuro-supportive Energy Therapy Device for Treating Neurodegenerative Disorders

School of Earth and Environment, Rowan University, NJ 08028 New Jersey, United States
Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland
Saint Louis University School of Medicine, 2600 Baguio City, Philippines
Show Author Information

Abstract

The prevalence of neurodegenerative disorders is rising as the population ages, and many ailments, such as depression, Parkinson's disease, Alzheimer's disease, autism spectrum disorder, and multiple sclerosis, have intricate underlying mechanisms that are still poorly understood. The Neuron Foundry Mach 8 is a multi-modal neuro-supportive energy therapy device designed to treat neurodegenerative disorders through daily sessions. This device proposes to deliver safe and controlled energy therapy through multiple therapeutic pathways, including stimulating brain mitochondrial energy, supporting homeostasis within the brain's immune system, increasing melatonin production within neuronal mitochondria, and triggering cellular communication through the brain's white matter. By combining these unique energy-based treatments, this device holds promising potential for slowing, stopping, reversing, or at least reducing the effects of neurodegenerative diseases.

References

[1]
van Schependom J, D’Haeseleer M. Advances in neurodegenerative diseases. J Clin Med 2023, 12(5): 1709.
[2]
Feigin VL, Vos T, Nichols E, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 2020, 19(3): 255–265.
[3]
Durães F, Pinto M, Sousa E. Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals 2018, 11(2): 44.
[4]
Sheikh S, Safia, Haque E, et al. Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions. J Neurodegener Dis 2013, 2013: 563481.
[5]
Kern JK, Geier DA, Sykes LK, et al. Evidence of neurodegeneration in autism spectrum disorder. Transl Neurodegener 2013, 2(1): 17.
[6]
Khan SA, Khan SA, Narendra AR, et al. Alzheimer’s disease and autistic spectrum disorder: is there any association? CNS Neurol Disord Drug Targets 2016, 15(4): 390–402.
[7]
Group TA. ALS untangled No. 20: the deanna protocol. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(4): 319–323.
[8]
Terry W, Robert R. The wahls diet for multiple sclerosis: a clinical conversation with terry wahls, MD, and Robert rountree, MD. Altern Complementary Ther 2017, 23(3): 79–86.
[9]
Tan DX, Manchester L, Qin LL, et al. Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. Int J Mol Sci 2016, 17(12): 2124.
[10]
Nieminen JO, Sinisalo H, Souza VH, et al. Multi-locus transcranial magnetic stimulation system for electronically targeted brain stimulation. Brain Stimul 2022, 15(1): 116–124.
[11]
Perkins KL. Cell-attached voltage-clamp and current-clamp recording and stimulation techniques in brain slices. J Neurosci Meth 2006, 154(1/2): 1–18.
[12]
Young J, Zoghi M, Khan F, et al. The effect of transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis: randomized controlled trial. Pain Med 2020, 21(12): 3451–3457.
[13]
Jeong H, Im JJ, Park JS, et al. A pilot clinical study of low-intensity transcranial focused ultrasound in Alzheimer’s disease. Ultrasonography 2021, 40(4): 512–519.
[14]
G.M. Edelman, Bright air, brilliant fire: On the matter of the mind, Basic Books, New York, NY, US, 1992.
[15]
Grafton ST, de C Hamilton AF. Evidence for a distributed hierarchy of action representation in the brain. Hum Mov Sci 2007, 26(4): 590–616.
[16]
Miller BL, Boone K, Cummings JL, et al. Functional correlates of musical and visual ability in frontotemporal dementia. Br J Psychiatry 2000, 176(5): 458–463.
[17]
Vickers AJ, Vertosick EA, Lewith G, et al. Acupuncture for chronic pain: update of an individual patient data meta-analysis. J Pain 2018, 19(5): 455–474.
[18]
Thrane S, Cohen SM. Effect of Reiki therapy on pain and anxiety in adults: an In-depth literature review of randomized trials with effect size calculations. Pain Manag Nurs 2014, 15(4): 897–908.
[19]
Jain S, Mills PJ. Biofield therapies: helpful or full of hype? A best evidence synthesis. Int J Behav Med 2010, 17(1): 1–16.
[20]
Amor S, Puentes F, Baker D, et al. Inflammation in neurodegenerative diseases. Immunology 2010, 129(2): 154–169.
[21]
Amor S, Peferoen LAN, Vogel DYS, et al. Inflammation in neurodegenerative diseases–an update. Immunology 2014, 142(2): 151–166.
[22]
Levin M. Molecular bioelectricity in developmental biology: new tools and recent discoveries. BioEssays 2012, 34(3): 205–217.
[23]
Rubik B. The biofield hypothesis: its biophysical basis and role in medicine. J Altern Complementary Med 2002, 8(6): 703–717.
[24]
Dotta BT, Buckner CA, Lafrenie RM, et al. Photon emissions from human brain and cell culture exposed to distally rotating magnetic fields shared by separate light-stimulated brains and cells. Brain Res 2011, 1388: 77–88.
[25]
Oschman JL. Electricity and magnetism in Diagnosis and therapeutics. In Energy Medicine. Amsterdam: Elsevier, 2016, pp 75–99.
[26]
Inglese M, Petracca M. Imaging multiple sclerosis and other neurodegenerative diseases. Prion 2013, 7(1): 47–54.
[27]
Silva J, Monge-Fuentes V, Gomes F, et al. Pharmacological alternatives for the treatment of neurodegenerative disorders: wasp and bee venoms and their components as new neuroactive tools. Toxins 2015, 7(8): 3179–3209.
[28]
Dhamija R, Saluja A, Goyal V. Multi-modal rehabilitation therapy in Parkinson’s disease and related disorders. Ann Indian Acad Neurol 2023, 26(7): 15.
[29]
Bisht B, Darling W, White E, et al. Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study. Degener Neurol Neuromuscul Dis 2017, 7: 79–93.
[30]
Adey WR. Biological effects of electromagnetic fields. J Cell Biochem 1993, 51(4): 410–416.
[31]
Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab 2012, 26(6): 711–723.
[32]
Rango M, Bresolin N. Brain mitochondria, aging, and Parkinson’s disease. Genes 2018, 9(5): 250.
[33]
Zhou ZQ, Austin G, Young L, et al. Mitochondrial metabolism in major neurological diseases. Cells 2018, 7(12): 229.
[34]
Han RR, Liang J, Zhou B. Glucose metabolic dysfunction in neurodegenerative diseases—new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming. Int J Mol Sci 2021, 22(11): 5887.
[35]
Jensen NJ, Wodschow HZ, Nilsson M, et al. Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases. Int J Mol Sci 2020, 21(22): 8767.
[36]
Ailioaie LM, Ailioaie C, Litscher G. Photobiomodulation in Alzheimer’s disease—a complementary method to state-of-the-art pharmaceutical formulations and nanomedicine? Pharmaceutics 2023, 15(3): 916.
[37]
Sun WJ, Yan JQ, Wu JN, et al. Efficacy and safety of light therapy as a home treatment for motor and non-motor symptoms of parkinson disease: a meta-analysis. Med Sci Monit 2021, 28: e935074.
[38]
Arnold S. Cytochrome c oxidase and its role in neurodegeneration and neuroprotection[M]//Kadenbach B. Mitochondrial Oxidative Phosphorylation. New York: Springer, 2012: 305-339.
[39]
Irnich D, Winklmeier S, Beyer A, et al. Electric stimulation acupuncture in peripheral neuropathic pain syndromes. Clinical pilot study on analgesic effectiveness. Schmerz 2002, 16(2): 114–120.
[40]
Bachiller S, Jiménez-Ferrer I, Paulus A, et al. Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci 2018, 12: 488.
[41]
Machado V, Zöller T, Attaai A, et al. Microglia-mediated neuroinflammation and neurotrophic factor-induced protection in the MPTP mouse model of Parkinson’s disease-lessons from transgenic mice. Int J Mol Sci 2016, 17(2): 151.
[42]
Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol 2018, 217(2): 459–472.
[43]
Kraft AD, Harry GJ. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 2011, 8(7): 2980–3018.
[44]
Geloso MC, Corvino V, Marchese E, et al. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci 2017, 9: 242.
[45]
Joers V, Tansey MG, Mulas G, et al. Microglial phenotypes in Parkinson’s disease and animal models of the disease. Prog Neurobiol 2017, 155: 57–75.
[46]
Dinetz E. Case series of three neurological side effects in younger-aged individuals after pfizer’s mRNA vaccine. Cureus 2022, 14(4): e23779.
[47]
Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in alzheimers disease. CNS Neurol Disord Drug Targets 2010, 9(2): 156–167.
[48]
Norris GT, Kipnis J. Immune cells and CNS physiology: Microglia and beyond. J Exp Med 2019, 216(1): 60–70.
[49]
Cekici A, Kantarci A, Hasturk H, et al. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000 2014, 64(1): 57–80.
[50]
Braidy N, Alicajic H, Pow D, et al. Potential mechanism of cellular uptake of the excitotoxin quinolinic acid in primary human neurons. Mol Neurobiol 2021, 58(1): 34–54.
[51]
Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012, 26(3): 383–392.
[52]
Wang WY, Tan MS, Yu JT, et al. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med 2015, 3(10): 136.
[53]
Shao FJ, Wang XY, Wu HJ, et al. Microglia and neuroinflammation: crucial pathological mechanisms in traumatic brain injury-induced neurodegeneration. Front Aging Neurosci 2022, 14: 825086.
[54]
Lively S, Schlichter LC. Microglia responses to pro-inflammatory stimuli (LPS, IFNγ+TNFα) and reprogramming by resolving cytokines (IL-4, IL-10). Front Cell Neurosci 2018, 12: 215.
[55]
Reiter RJ, Rosales-Corral S, Tan DX, et al. Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideas. Cell Mol Life Sci 2017, 74(21): 3863–3881.
[56]
Reiter R, Sharma R, Rosales-Corral S, et al. Melatonin and pathological cell interactions: mitochondrial glucose processing in cancer cells. Int J Mol Sci 2021, 22(22): 12494.
[57]
Agil A, Reiter RJ, Jiménez-Aranda A, et al. Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats. J Pineal Res 2013, 54(4): 381–388.
[58]
Yeager RL, Oleske DA, Sanders RA, et al. Melatonin as a principal component of red light therapy. Med Hypotheses 2007, 69(2): 372–376.
[59]
Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008, 31(7): 361–370.
[60]
Chorghay Z, Káradóttir RT, Ruthazer ES. White matter plasticity keeps the brain in tune: axons conduct while Glia wrap. Front Cell Neurosci 2018, 12: 428.
[61]
Syková E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev 2008, 88(4): 1277–1340.
[62]
ALSUntangled Group, Fournier C, Bedlack B, et al. ALS Untangled No. 20: the Deanna protocol. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(4):319-23.
[63]
Dong DY, Zielke HR, Yeh D, et al. Cellular stress and apoptosis contribute to the pathogenesis of autism spectrum disorder. Autism Res 2018, 11(7): 1076–1090.
[64]
Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cellular Molecular Medi 2008, 12(6a): 2263–2280.
[65]
Majd S, Power JH, Grantham HJM. Neuronal response in Alzheimer’s and Parkinson’s disease: the effect of toxic proteins on intracellular pathways. BMC Neurosci 2015, 16(1): 69.
[66]
Pagano G, Pallardó FV, Lyakhovich A, et al. Aging-related disorders and mitochondrial dysfunction: a critical review for prospect mitoprotective strategies based on mitochondrial nutrient mixtures. Int J Mol Sci 2020, 21(19): 7060.
[67]
Shaffer J. Neuroplasticity and clinical practice: building brain power for health. Front Psychol 2016, 7: 1118.
[68]
Kolb B, Gibb R. Brain plasticity and behaviour in the developing brain. J Can Acad Child Adolesc Psychiatry 2011, 20(4): 265–276.
[69]
Rusu SI, Pennartz CMA. Learning, memory and consolidation mechanisms for behavioral control in hierarchically organized cortico-basal Ganglia systems. Hippocampus 2020, 30(1): 73–98.
[70]
Dickerson BC, Eichenbaum H. The episodic memory system: neurocircuitry and disorders. Neuropsychopharmacology 2010, 35(1): 86–104.
[71]
R Hamblin M. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys 2017, 4(3): 337–361.
[72]
Kahraman N, Yümün G, Demir D, et al. Detection of residual varicose veins with near infrared light in the early period after varicose surgery and near infrared light assisted sclerotherapy. Vascular 2022, 30(6): 1174–1181.
[73]
Hamblin MR. Could photobiomodulation treat autism spectrum disorder? Photobiomodulation Photomed Laser Surg 2022, 40(6): 367–369.
[74]
Johnstone DM, Moro C, Stone J, et al. Turning on lights to stop neurodegeneration: the potential of near infrared light therapy in Alzheimer’s and Parkinson’s disease. Front Neurosci 2016, 9: 500.
[75]
Rojas JC, Bruchey AK, Gonzalez-Lima F. Low-level light therapy improves cortical metabolic capacity and memory retention. J Alzheimers Dis 2012, 32(3): 741–752.
[76]
Stepanov YV, Golovynska I, Zhang RL, et al. Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease. Alzheimers Res Ther 2022, 14(1): 84.
[77]
Akimoto K, Hu AL, Yamaguchi T, et al. Effect of 528 hz music on the endocrine system and autonomic nervous system. Health 2018, 10(9): 1159–1170.
[78]
Kumar M, Abhayapala TD, Samarasinghe P. A preliminary investigation on frequency dependant cues for human emotions. Acoustics 2022, 4(2): 460–468.
[79]
Sagol AD. Music Theory: 432 Hz Tuning - Separating Fact From Fiction. 2016. Available at: https://ask.audio/articles/music-theory-432-hz-tuning-separating-fact-from-fiction (accessed 1 Nov 2023).
[80]
Babayi Daylari T, Riazi GH, Pooyan S, et al. Influence of various intensities of 528Hz sound-wave in production of testosterone in rat’s brain and analysis of behavioral changes. Genes Genom 2019, 41(2): 201–211.
[81]
Ross B, Lopez MD. 40-Hz Binaural beats enhance training to mitigate the attentional blink. Sci Rep 2020, 10: 7002.
[82]
Jirakittayakorn N, Wongsawat Y. Brain responses to 40-Hz binaural beat and effects on emotion and memory. Int J Psychophysiol 2017, 120: 96–107.
[83]
Meditationalstate, Scientists CAN’T Explain Why This Audio HEALS People! 111Hz • Binaural Beats. 2023. Available at: https://meditationalstate.com/product/scientists-cant-explain-why-this-audio-heals-people-111hz-binaural-beats/ (accessed 1 Nov 2023).
[84]
Zhang YQ, Zhang ZY, Luo L, et al. 40 hz light flicker alters human brain electroencephalography microstates and complexity implicated in brain diseases. Front Neurosci 2021, 15: 777183.
[85]
Ismail R, Hansen AK, Parbo P, et al. The effect of 40-hz light therapy on amyloid load in patients with prodromal and clinical Alzheimer’s disease. Int J Alzheimers Dis 2018, 2018: 6852303.
[86]
Wu CY, Yang LM, Feng S, et al. Therapeutic non-invasive brain treatments in Alzheimer’s disease: recent advances and challenges. Inflamm Regen 2022, 42(1): 1–32.
[87]
Curtis D, Fallows S, Morris M, et al. The efficacy of frequency specific microcurrent therapy on delayed onset muscle soreness. J Bodyw Mov Ther 2010, 14(3): 272–279.
[88]
McMakin CR, Oschman JL. Visceral and somatic disorders: tissue softening with frequency-specific microcurrent. J Altern Complementary Med 2013, 19(2): 170–177.
[89]
Vincent A, Whipple MO, Low PA, et al. Patients with fibromyalgia have significant autonomic symptoms but modest autonomic dysfunction. PM&R 2016, 8(5): 425–435.
[90]
Ravazzani P, Ruohonen J, Grandori F, et al. Magnetic stimulation of the nervous system: induced electric field in unbounded, semi-infinite, spherical, and cylindrical media. Ann Biomed Eng 1996, 24(5): 606–616.
[91]
Trofè A, Piras A, Muehsam D, et al. Effect of pulsed electromagnetic fields (PEMFs) on muscular activation during cycling: a single-blind controlled pilot study. Healthcare 2023, 11(6): 922.
[92]
Ross CL, Zhou Y, McCall CE, et al. The use of pulsed electromagnetic field to modulate inflammation and improve tissue regeneration: a review. Bioelectricity 2019, 1(4): 247–259.
[93]
Harman J, Hill T, Treating Autism Spectrum Disorder Using Pulsed EMF Therapy: A Case Series Report, Asia Pacific Journal of Neurotherapy 2019, 1: 21–26.
[94]
Kantor J, Campbell EA, Kantorová L, et al. Exploring vibroacoustic therapy in adults experiencing pain: a scoping review. BMJ Open 2022, 12(4): e046591.
[95]
Bartel L, Mosabbir A. Possible mechanisms for the effects of sound vibration on human health. Healthcare 2021, 9(5): 597.
[96]
Yang LD, Youngblood H, Wu CY, et al. Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. Transl Neurodegener 2020, 9(1): 19.
[97]
Bertram L. The genetic epidemiology of neurodegenerative disease. J Clin Investig 2005, 115(6): 1449–1457.
[98]
Bohr N. the atomic theory and the fundamental principles underlying the description of nature. In Niels Bohr Collected Works. Amsterdam: Elsevier, 1985, pp 219–253.
[99]
Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 2010, 20(Suppl 2): S265–S279.
[100]
Nicholls DJ, Ferguson, SJ. Bioenergetics, 3rd edn. Academic Press, London, 2002.
[101]
Zhang JX, Wang XL, Vikash V, et al. ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev 2016, 2016: 4350965.
[102]
IBM-Corp, IBM SPSS Statistics, IBM Corp, Armonk, NY, 2019.
[103]
Origin(Pro), OriginLab, OriginLab Corporation, Northampton, MA, USA, 2021.
[104]
Schiffer F, Johnston AL, Ravichandran C, et al. Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct 2009, 5(1): 46.
[105]
Ancoli-Israel S, Martin JL, Gehrman P, et al. Effect of light on agitation in institutionalized patients with severe alzheimer disease. Am J Geriatr Psychiatry 2003, 11(2): 194–203.
[106]
Fontana Gasio P. Dawn–dusk simulation light therapy of disturbed circadian rest–activity cycles in demented elderly. Exp Gerontol 2003, 38(1/2): 207–216.
[107]
Arroyo-Anlló EM, Dauphin S, Fargeau MN, et al. Music and emotion in Alzheimer’s disease. Alzheimers Res Ther 2019, 11(1): 69.
[108]
Calomeni MR, Furtado da Silva V, Velasques BB, et al. Modulatory effect of association of brain stimulation by light and binaural beats in specific brain waves. Clin Pract Epidemiol Ment Health 2017, 13(1): 134–144.
[109]
Sharpe RLS, Mahmud M, Kaiser MS, et al. Gamma entrainment frequency affects mood, memory and cognition: an exploratory pilot study. Brain Inform 2020, 7(1): 17.
[110]
Agger MP, Danielsen ER, Carstensen MS, et al. Safety, feasibility, and potential clinical efficacy of 40 Hz invisible spectral flicker versus placebo in patients with mild-to-moderate Alzheimer’s disease: a randomized, placebo-controlled, double-blinded, pilot study. J Alzheimers Dis 2023, 92(2): 653–665.
[111]
Cimenser A, Hempel E, Travers T, et al. Sensory-evoked 40-hz gamma oscillation improves sleep and daily living activities in Alzheimer’s disease patients. Front Syst Neurosci 2021, 15: 746859.
[112]
He QL, Colon-Motas KM, Pybus AF, et al. A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer’s disease. A&D Transl Res & Clin Interv 2021, 7(1): e12178.
[113]
Kim YJ, Kim HR, Jung YH, et al. Effects of electrical automatic massage on cognition and sleep quality in Alzheimer’s disease spectrum patients: a randomized controlled trial. Yonsei Med J 2021, 62(8): 717.
[114]
Satoh S, Kajiwara M, Kiyokawa E, et al. Rivastigmine patch and massage for Alzheimer’s disease patients. Geriatrics Gerontology Int 2013, 13(2): 515–516.
[115]
Videnovic A, Klerman EB, Wang W, et al. Timed light therapy for sleep and daytime sleepiness associated with parkinson disease. JAMA Neurol 2017, 74(4): 411.
[116]
Liebert A, Bicknell B, Laakso EL, et al. Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study. BMC Neurol 2021, 21(1): 256.
[117]
Calvano A, Timmermann L, Loehrer PA, et al. Binaural acoustic stimulation in patients with Parkinson’s disease. Front Neurol 2023, 14: 1167006.
[118]
González D, Bruña R, Martínez-Castrillo JC, et al. First longitudinal study using binaural beats on parkinson disease. Int J Neur Syst 2023, 33(6): 2350027.
[119]
Gálvez G, Recuero M, Canuet L, et al. Short-term effects of binaural beats on EEG power, functional connectivity, cognition, gait and anxiety in Parkinson’s disease. Int J Neural Syst 2018, 28(5): 1750055.
[120]
Zarkali A, Lees AJ, Weil RS. Flickering stimuli do not reliably induce visual hallucinations in Parkinson’s disease. J Park Dis 2019, 9(3): 631–635.
[121]
Morberg BM, Malling AS, Jensen BR, et al. Effects of transcranial pulsed electromagnetic field stimulation on quality of life in Parkinson’s disease. Euro J Neurology 2018, 25(7): 963.
[122]
Jensen BR, Malling ASB, Schmidt SI, et al. Long-term treatment with transcranial pulsed electromagnetic fields improves movement speed and elevates cerebrospinal erythropoietin in Parkinson’s disease. PLoS One 2021, 16(4): e0248800.
[123]
Morberg BM, Malling AS, Jensen BR, et al. Parkinson’s disease and transcranial pulsed electromagnetic fields: a randomized clinical trial. Mov Disord 2017, 32(4): 625–626.
[124]
Malling ASB, Morberg BM, Wermuth L, et al. Effect of transcranial pulsed electromagnetic fields (T-PEMF) on functional rate of force development and movement speed in persons with Parkinson’s disease: a randomized clinical trial. PLoS One 2018, 13(9): e0204478.
[125]
Morberg BM, Malling AS, Jensen BR, et al. The Hawthorne effect as a pre-placebo expectation in Parkinsons disease patients participating in a randomized placebo-controlled clinical study. Nord J Psychiatry 2018, 72(6): 442–446.
[126]
Khedr EM, Farweez HM, Islam H. Therapeutic effect of repetitive transcranial magnetic stimulation on motor function in Parkinson’s disease patients. Euro J Neurology 2003, 10(5): 567–572.
[127]
Mancini M, Smulders K, Harker G, et al. Assessment of the ability of open- and closed-loop cueing to improve turning and freezing in people with Parkinson’s disease. Sci Rep 2018, 8: 12773.
[128]
Klaver EC, van Vugt JPP, Bloem BR, et al. Good vibrations: tactile cueing for freezing of gait in Parkinson’s disease. J Neurol 2023, 270(7): 3424–3432.
[129]
Donoyama N, Ohkoshi N. Effects of traditional Japanese massage therapy on various symptoms in patients with Parkinson’s disease: a case-series study. J Altern Complementary Med 2012, 18(3): 294–299.
[130]
Törnhage CJ, Skogar Ö, Borg A, et al. Short- and long-term effects of tactile massage on salivary cortisol concentrations in Parkinson’s disease: a randomised controlled pilot study. BMC Complementary Altern Med 2013, 13(1): 357.
[131]
Paterson C, A Allen J, Browning M, et al. A pilot study of therapeutic massage for people with Parkinson’s disease: the added value of user involvement. Complementary Ther Clin Pract 2005, 11(3): 161–171.
[132]
Craig LH, Svircev A, Haber M, et al. Controlled pilot study of the effects of neuromuscular therapy in patients with Parkinson’s disease. Mov Disord 2006, 21(12): 2127–2133.
[133]
Mateen FJ, Vogel AC, Kaplan TB, et al. Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial. J Neurol 2020, 267(8): 2319–2327.
[134]
Voggenberger L, Böck M, Moser D, et al. Bright light therapy as a non-pharmacological treatment option for multiple sclerosis-related fatigue: a randomized sham-controlled trial. Mult Scler J Exp Transl Clin 2022, 8(4): 20552173221133262.
[135]
Shetty GM, Rawat P, Sharma A. Effect of adjuvant frequency-specific microcurrents on pain and disability in patients treated with physical rehabilitation for neck and low back pain. J Bodyw Mov Ther 2020, 24(4): 168–175.
[136]
Granja-Domínguez A, Hochsprung A, Luque-Moreno C, et al. Effects of pulsed electromagnetic field therapy on fatigue, walking performance, depression, and quality of life in adults with multiple sclerosis: a randomized placebo-controlled trial. Braz J Phys Ther 2022, 26(5): 100449.
[137]
Hochsprung A, Escudero-Uribe S, Ibáñez-Vera AJ, et al. Effectiveness of monopolar dielectric transmission of pulsed electromagnetic fields for multiple sclerosis–related pain: a pilot study. Neurol Engl Ed 2021, 36(6): 433–439.
[138]
Mostert S, Kesselring J. Effect of pulsed magnetic field therapy on the level of fatigue in patients with multiple sclerosis - a randomized controlled trial. Mult Scler 2005, 11(3): 302–305.
[139]
Haase R, Piatkowski J, Ziemssen T. Long-term effects of Bio-Electromagnetic-Energy Regulation therapy on fatigue in patients with multiple sclerosis. Altern Ther Health Med 2011, 17(6): 22–28.
[140]
Negahban H, Rezaie S, Goharpey S. Massage therapy and exercise therapy in patients with multiple sclerosis: a randomized controlled pilot study. Clin Rehabil 2013, 27(12): 1126–1136.
[141]
McClurg D, Goodman K, Hagen S, et al. Abdominal massage for neurogenic bowel dysfunction in people with multiple sclerosis (AMBER - Abdominal Massage for Bowel Dysfunction Effectiveness Research): study protocol for a randomised controlled trial. Trials 2017, 18(1): 150.
[142]
Lee JE, Bisht B, Hall MJ, et al. A multimodal, nonpharmacologic intervention improves mood and cognitive function in people with multiple sclerosis. J Am Coll Nutr 2017, 36(3): 150–168.
[143]
Bisht B, Darling WG, Grossmann RE, et al. A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. J Altern Complementary Med 2014, 20(5): 347–355.
[144]
Siev-Ner I, Gamus D, Lerner-Geva L, et al. Refiexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study. Mult Scler 2003, 9(4): 356–361.
[145]
Hughes CM, Smyth S, Lowe-Strong AS. Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomised sham-controlled clinical trial. Mult Scler 2009, 15(11): 1329–1338.
[146]
van Maanen A, Meijer AM, Smits MG, et al. Classical conditioning for preserving the effects of short melatonin treatment in children with delayed sleep: a pilot study. Nat Sci Sleep 2017, 9: 67–79.
[147]
Shi S., Wang J., Wang Y, et al. Effects of different types of visual music on the prefrontal hemodynamics of children with autism spectrum disorder based on functional near-infrared spectroscopy, Translational pediatrics 2023, 12(2): 162–171.
[148]
Leisman G, Machado C, Machado Y, et al. Effects of low-level laser therapy in autism spectrum disorder. In Advances in Experimental Medicine and Biology. Cham: Springer International Publishing, 2018, pp 111–130.
[149]
Carrick FR, Pagnacco G, Hankir A, et al. The treatment of autism spectrum disorder with auditory neurofeedback: a randomized placebo controlled trial using the mente autism device. Front Neurol 2018, 9: 537.
[150]
Johnston D, Egermann H, Kearney G. The use of binaural based spatial audio in the reduction of auditory hypersensitivity in autistic young people. Int J Environ Res Public Health 2022, 19(19): 12474.
[151]
Darwish ME, El-Beshlawy HW, Ramadan ES, et al. Study of the role of the transcranial magnetic stimulation on language progress in autism spectrum disorder. Egypt J Otolaryngol 2021, 37(1): 59.
[152]
Lu WP, Tsai WH, Lin LY, et al. The beneficial effects of massage on motor development and sensory processing in young children with developmental delay: a randomized control trial study. Dev Neurorehabilit 2019, 22(7): 487–495.
[153]
Piravej K, Tangtrongchitr P, Chandarasiri P, et al. Effects of Thai traditional massage on autistic children’s behavior. J Altern Complementary Med 2009, 15(12): 1355–1361.
[154]
Silva LMT, Cignolini A, Warren R, et al. Improvement in sensory impairment and social interaction in young children with autism following treatment with an original Qigong massage methodology. Am J Chin Med 2007, 35(3): 393–406.
[155]
Trivedi JK. Cognitive deficits in psychiatric disorders: current status. Indian J Psychiatry 2006, 48(1): 10.
[156]
Petzinger GM, Fisher BE, McEwen S, et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol 2013, 12(7): 716–726.
[157]
Sharew NT. The effect of multimodal non-pharmacological interventions on cognitive function improvement for people with dementia: a systematic review. Front Public Health 2022, 10: 894930.
[158]
Pagonabarraga J, Álamo C, Castellanos M, et al. Depression in major neurodegenerative diseases and strokes: a critical review of similarities and differences among neurological disorders. Brain Sci 2023, 13(2): 318.
[159]
Ray Chaudhuri K, Rojo JM, Schapira AHV, et al. A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One 2013, 8(2): e57221.
[160]
Lord C, Brugha TS, Charman T, et al. Autism spectrum disorder. Nat Rev Dis Primers 2020, 6: 5.
[161]
Chalah MA, Riachi N, Ahdab R, et al. Fatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulation. Front Cell Neurosci 2015, 9: 460.
[162]
Saniotis A, Henneberg M, Sawalma AR. Integration of nanobots into neural circuits As a future therapy for treating neurodegenerative disorders. Front Neurosci 2018, 12: 153.
[163]
Kaub L, Schmitz C. More than ninety percent of the light energy emitted by near-infrared laser therapy devices used to treat musculoskeletal disorders is absorbed within the first ten millimeters of biological tissue. Biomedicines 2022, 10(12): 3204.
[164]
Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov 2020, 19(9): 609–633.
Brain Science Advances
Pages 5-37
Cite this article:
McGlynn C, Dermawan D, Canonizado GM. Neuron Foundry Mach 8: A Concept of Multi-modal Neuro-supportive Energy Therapy Device for Treating Neurodegenerative Disorders. Brain Science Advances, 2024, 10(1): 5-37. https://doi.org/10.26599/BSA.2023.9050026

230

Views

23

Downloads

1

Crossref

Altmetrics

Received: 19 November 2023
Revised: 09 December 2023
Accepted: 14 December 2023
Published: 05 March 2024
© The authors 2023.

This article is published with open access at journals.sagepub.com/home/BSA

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Return